<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diffuse large B cell lymphoma (DLBCL): Second or later relapse or patients who are medically unfit
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arnold S Freedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan W Friedberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ann S LaCasce, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2882274469">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with diffuse large B cell lymphoma (DLBCL) are cured after initial treatment using
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         plus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (R-CHOP). However, nearly one-third of patients relapse after achieving a complete response (CR), and approximately 10 percent are refractory to initial therapy (ie, do not achieve CR).
        </p>
        <p>
         Relapsed or refractory (r/r) DLBCL can be cured in some patients with intensive treatments, such as chimeric antigen receptor (CAR)-T cell therapy or hematopoietic cell transplantation (HCT), but some patients do not respond adequately or subsequently relapse. Other patients are not candidates for intensive treatment because of limited medical fitness. Various treatments are used for patients with second or later relapse of DLBCL and patients with limited medical fitness; we encourage participation in a clinical trial for all.
        </p>
        <p>
         This topic discusses treatment of medically fit patients who have a second or later relapse of DLBCL and management of r/r DLBCL in patients who are not medically fit for intensive treatments.
        </p>
        <p>
         Management of medically fit patients with a first relapse or primary refractory DLBCL is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Autologous hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H481204361">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pretreatment evaluation of a patient with relapsed or refractory (r/r) DLBCL includes assessment of medical fitness, restaging, and estimation of prognosis.
        </p>
        <p class="headingAnchor" id="H3119093629">
         <span class="h2">
          Clinical and laboratory evaluation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History and physical examination
         </strong>
         – The presence of B symptoms (ie, fever, sweats, weight loss) and lymph node and/or organ involvement should be documented by history and physical examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Neurologic examination should be performed. Patients with abnormal findings on neurologic examination should undergo neuroimaging and lumbar puncture, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4720.html" rel="external">
          "Secondary central nervous system lymphoma: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hematology
         </strong>
         – Complete blood count (CBC) with leukocyte differential count
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chemistries
         </strong>
         – Serum electrolytes, glucose, blood urea nitrogen (BUN) and creatinine, calcium, uric acid, and liver function tests, including lactate dehydrogenase (LDH)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infectious diseases
         </strong>
         – Human immunodeficiency virus (HIV) and hepatitis B testing
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnancy testing
         </strong>
         – If appropriate
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2379814203">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A biopsy is generally performed to confirm the diagnosis of r/r DLBCL and exclude other diagnoses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected first relapse
         </strong>
         – For patients with an apparent relapse after previously achieving a complete response (CR; based on positron emission tomography [PET]/computed tomography [CT]  (
         <a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">
          table 1
         </a>
         )), a biopsy should be performed to confirm the diagnosis, exclude other conditions (eg, other types of lymphoma, carcinoma, sarcoidosis, tuberculosis, fungal infection), and to assess for disease transformation or acquisition of new mutations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second or later relapse
         </strong>
         – For patients with a second or later relapse, a repeat biopsy may not be required if other diagnoses can be excluded clinically. However, a biopsy should be performed to confirm a second relapse if it occurs following a CR to hematopoietic cell transplantation (HCT) or chimeric antigen receptor (CAR)-T cell therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suspected primary refractory disease
         </strong>
         – For patients who did not achieve a CR with initial therapy, a repeat biopsy is encouraged but may not be required if there was clear progression in the size and metabolic activity of a disease site. If a biopsy is not performed, morphology, immunophenotype, and cytogenetic/molecular features of the initial biopsy specimen should be reviewed to ensure that DLBCL was correctly diagnosed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H646556567">
         <span class="h2">
          Medical fitness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Assessment of medical fitness affects treatment decisions for r/r DLBCL. Age, per se, does not determine the level of medical fitness, but caution should be used when considering intensive therapy for patients ≥75 years old because comorbidities increase with age.
        </p>
        <p>
         Some patients are not fit for intensive treatment of primary refractory disease or first relapse because of comorbid conditions, while others who were previously fit may experience a functional decline after prior treatments or subsequent relapses.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment
         </strong>
         – Medical fitness is assessed with the following instruments:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Performance status
         </strong>
         – Eastern Cooperative Oncology Group (ECOG) performance scale  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physiologic fitness
         </strong>
         – Physiologic fitness (eg, comorbid conditions, activities of daily living, physical performance tests, cognition) as measured by the Charlson comorbidity index (CCI)  (
         <a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">
          table 3
         </a>
         ) or the HCT-specific comorbidity index  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fitness categories
         </strong>
         – We categorize patients with r/r DLBCL according to fitness for treatment, based on performance status (PS) and physiologic fitness. Chronic comorbid conditions should be weighted more heavily than transient medical complications of the lymphoma (eg, infection, heart failure exacerbated by anemia). The burden of r/r DLBCL can contribute to a lack of fitness, and in some cases, treatment may alleviate disease consequences/complications and enhance the patient's ability to tolerate and benefit from subsequent treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are no clear distinctions among fitness categories, and some measures of PS or physiologic fitness can apply to different categories. In selecting a category of fitness, we seek to protect frail patients from treatment that they are unlikely to tolerate, while not depriving others from the opportunity to achieve a meaningful response and prolonged survival.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Medically fit
         </strong>
         – Medically fit patients are judged to be able to tolerate intensive treatment, including HCT, based on
         <strong>
          both
         </strong>
         of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ECOG: 0 to 2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CCI: 0 to 2  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Management of medically fit individuals with first relapse or primary refractory DLBCL is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Medically unfit, but not frail
         </strong>
         – Patients who are medically unfit but not frail cannot tolerate autologous HCT, but they may be able to tolerate CAR-T cell therapy or antibody-based treatments. This category includes a broad range of physical function; some patients have only modest, recent, or transient impairment of functional status, while others have substantial comorbid illnesses, cognitive impairment, or other conditions that can affect their ability to tolerate treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We judge patients to be medically unfit but not frail if
         <strong>
          either
         </strong>
         of the following applies:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ECOG: 3  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CCI: 3  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Frail
         </strong>
         – Frail patients are those whose debility or comorbid conditions would not permit treatment aimed at modifying the disease course, as reflected by
         <strong>
          both
         </strong>
         the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         ECOG: ≥3  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         CCI: ≥3  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Note that our use of the term "frail" for managing patients with hematologic malignancies may differ from other definitions of frailty. (See
         <a class="medical medical_review" href="/z/d/html/3010.html" rel="external">
          "Frailty", section on 'Concepts and definitions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other approaches for assessing fitness have been described. As an example, the Elderly Prognostic Index (EPI) integrates age with a simplified comprehensive geriatric assessment of functional activities and comorbidities; in this model, by definition, all patients ≥80 years are classified as unfit or frail [
         <a href="#rid1">
          1
         </a>
         ]. The three categories of fitness in the EPI have been validated as independent prognostic factors for survival [
         <a href="#rid2">
          2,3
         </a>
         ]. Clinician-administered or patient-completed instruments can be useful to assess the risk for falls, cognitive deficits, depression, functional decline, and death; these tools can also complement a formal geriatric assessment for judging medical fitness in older patients who may have a range of frailties [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Geriatric assessment may be useful for judging medical fitness of some patients in this setting [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4530.html" rel="external">
          "Acute myeloid leukemia: Management of medically unfit adults", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p>
         Other considerations for treatment of older or frail patients are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">
          "Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Older adults'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H555515115">
         <span class="h2">
          Restaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restaging  (
         <a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">
          table 5
         </a>
         ) is based on clinical evaluation and PET/CT, according to the Lugano criteria  (
         <a class="graphic graphic_table graphicRef66651" href="/z/d/graphic/66651.html" rel="external">
          table 6
         </a>
         ). Disease stage at relapse should be designated by subscript R (
         <sub>
          R
         </sub>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – PET/CT should be scored according to the five-point (Deauville) scale  (
         <a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow
         </strong>
         – Bone marrow examination is preferred, but it is not required for restaging all patients with r/r DLBCL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PET is generally a good predictor for marrow involvement by DLBCL. However, if autologous HCT is a consideration, bone marrow examination is usually performed prior to transplantation to assess possible myelodysplasia or acute myeloid leukemia, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Autologous hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Bone marrow should be analyzed by microscopy, cytogenetics (using fluorescence in situ hybridization or Giemsa-stained chromosomes), and molecular studies, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2428460236">
         <span class="h2">
          Prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A modification of International Prognostic Index (IPI) that categorizes patients according to age cohort should be applied in this setting; this modified index has greater discriminatory power for older adults than the original IPI [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Outcomes are generally poor for patients who relapse following autologous HCT and for those who are not eligible for transplantation or other intensive therapies [
         <a href="#rid6">
          6-8
         </a>
         ]. A multicenter retrospective study (SCHOLAR-1) of 636 patients (from the pre-CAR-T era) reported 26 percent overall response rate, 7 percent CR, and six-month median overall survival among patients who did not achieve at least a partial response after one of the following: &gt;4 cycles of initial therapy, two cycles of subsequent therapy, or relapse ≤12 months from autologous HCT [
         <a href="#rid9">
          9
         </a>
         ]. Outcomes were especially poor for patients with refractory DLBCL.
        </p>
        <p class="headingAnchor" id="H3319602957">
         <span class="h1">
          MEDICALLY FIT WITH SECOND OR LATER RELAPSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment for medically fit patients with second or later relapse is stratified according to whether the patient previously received CD19-directed chimeric antigen receptor (CAR)-T cell therapy  (
         <a class="graphic graphic_algorithm graphicRef142190" href="/z/d/graphic/142190.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         For patients with documented central nervous system (CNS) involvement, CNS disease should be controlled before or at the time of systemic treatment. Management of CNS involvement by DLBCL is described separately. (See
         <a class="medical medical_review" href="/z/d/html/4720.html" rel="external">
          "Secondary central nervous system lymphoma: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/89417.html" rel="external">
          "Secondary central nervous system lymphoma: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H781539593">
         <span class="h2">
          No prior chimeric antigen receptor T cell therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For medically fit patients with second or later relapse of DLBCL who did not previously receive CAR-T cell therapy, we suggest CD19-directed CAR-T cell therapy  (
         <a class="graphic graphic_algorithm graphicRef142190" href="/z/d/graphic/142190.html" rel="external">
          algorithm 1
         </a>
         ) rather than other approaches, based on successful outcomes with CAR-T cell therapy as second-line therapy for patients with primary refractory disease or first relapse &lt;12 months after initial treatment, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         .)
        </p>
        <p>
         For patients who require bridging therapy to control disease prior to CAR-T cell therapy, we generally avoid CD19-directed therapies (eg,
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         , loncastuximab); these treatments are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         .)
        </p>
        <p>
         Randomized trials of patients with first relapse or primary refractory DLBCL reported that
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          axicabtagene ciloleucel
         </a>
         (axi-cel) and
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         (liso-cel) achieved superior survival compared with autologous hematopoietic cell transplantation (HCT) [
         <a href="#rid10">
          10,11
         </a>
         ]; a third randomized trial reported that
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         (tisa-cel) was not superior to autologous HCT [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The various CD19-directed CAR-T cell products have not been compared head-to-head, but all are associated with an objective response in at least half of patients with relapsed or refractory (r/r) DLBCL. However, all CAR-T cell products can cause potentially life-threatening adverse events (AEs), including cytokine release syndrome (CRS) and neurologic toxicity. Preliminary reports suggest that liso-cel may be associated with less toxicity than axi-cel or tisa-cel. The choice of CAR-T cell agent may be influenced by availability, manufacturing time, and institutional preference.
        </p>
        <p>
         Axi-cel, liso-cel, and tisa-cel are approved by the US Food and Drug Administration (FDA) for treatment of r/r DLBCL after ≥2 prior treatments.
        </p>
        <p>
         Toxicity and indications for individual CAR-T cell products are described below. (See
         <a class="local">
          'Chimeric antigen receptor T cell therapy'
         </a>
         below.)
        </p>
        <p>
         If necessary, treatment with a bispecific antibody, polatuzumab (if not previously administered), or low-dose chemotherapy may be used as bridging therapy. (See
         <a class="local">
          'Bispecific antibody therapy'
         </a>
         below and
         <a class="local">
          'Polatuzumab/bendamustine/rituximab'
         </a>
         below and
         <a class="local">
          'Lower-intensity chemotherapy'
         </a>
         below.)
        </p>
        <p>
         Detailed discussion of outcomes with individual CD19-directed CAR-T cell agents for r/r DLBCL are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Relapse &lt;12 months or primary refractory DLBCL'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32011300">
         <span class="h2">
          Prior chimeric antigen receptor T cell therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For a medically fit patient who relapses after receiving CAR-T cell therapy, we suggest bispecific antibody therapy (also called bispecific T cell engager therapy) rather than HCT or other approaches  (
         <a class="graphic graphic_algorithm graphicRef142190" href="/z/d/graphic/142190.html" rel="external">
          algorithm 1
         </a>
         ). This suggestion is based on the more favorable balance of efficacy and toxicity with bispecific antibody therapy.
        </p>
        <p>
         No randomized trials have directly compared treatments in this setting, and no approach has proven to be clearly superior. Prognosis generally worsens with increasing episodes of relapse, but some patients achieve long-term disease control using bispecific antibody therapy.
        </p>
        <p>
         Management of relapse after CAR-T cell therapy is challenging, and treatment must be individualized. The approach is informed by prior treatments, comorbid conditions, institutional experience, and patient preference. Other acceptable options include antibody-based therapies (eg,
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         ,
         <a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">
          polatuzumab vedotin
         </a>
         , loncastuximab) or allogeneic HCT; for patients who seek symptom relief without an expectation of longer-term disease control, lower-intensity chemotherapy or palliative approaches are appropriate.
        </p>
        <p>
         Bispecific antibody therapy is discussed below. (See
         <a class="local">
          'Bispecific antibody therapy'
         </a>
         below.)
        </p>
        <p>
         Other antibody-based treatments are discussed below. (See
         <a class="local">
          'Other antibody-based therapies'
         </a>
         below.)
        </p>
        <p>
         Allogeneic HCT should only be offered to fit patients who achieve a complete response (CR) or near-CR after salvage therapy. (See
         <a class="local">
          'Allogeneic hematopoietic cell transplantation'
         </a>
         below.)
        </p>
        <p>
         Lower-intensity chemotherapy and palliative treatments are discussed below. (See
         <a class="local">
          'Lower-intensity chemotherapy'
         </a>
         below and
         <a class="local">
          'Palliative treatments'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1997997047">
         <span class="h1">
          MEDICALLY UNFIT, BUT NOT FRAIL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of relapsed or refractory (r/r) DLBCL in patients who are medically unfit but not frail must be individualized, as this category includes patients with a wide range of general fitness, comorbid conditions, and performance status.
        </p>
        <p>
         Treatment is stratified according to whether this is first relapse or primary refractory DLBCL versus second or later relapse.
        </p>
        <p class="headingAnchor" id="H394092743">
         <span class="h2">
          First relapse or primary refractory DLBCL
         </span>
         <span class="headingEndMark">
          —
         </span>
         For first relapse or primary refractory DLBCL in patients who are medically unfit but not frail, we suggest treatment with
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         (liso-cel) rather than other CD19-directed chimeric antigen receptor (CAR)-T cell products, bispecific antibody therapy, other antibody-based treatments, or lower-intensity chemotherapy.
        </p>
        <p>
         Where liso-cel is not available, we generally favor bispecific antibody therapy or another antibody-based treatment (eg,
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         ,
         <a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">
          polatuzumab vedotin
         </a>
         , loncastuximab). Selection of an alternative approach is acceptable based on product availability, manufacturing time, comorbid conditions, performance status, and patient preference.
        </p>
        <p>
         A trial of liso-cel versus autologous hematopoietic cell transplantation (HCT) for r/r DLBCL suggested that liso-cel has similar efficacy but less toxicity than other commercially available, CD19-directed CAR-T cell products [
         <a href="#rid10">
          10-12
         </a>
         ]. Liso-cel is also associated with improved patient-reported quality of life, cognitive function, fatigue, and pain [
         <a href="#rid13">
          13
         </a>
         ]. No studies have directly compared liso-cel with other treatments in this setting, but in the TRANSCEND NHL001 study, liso-cel was associated with a 73 percent overall response rate (ORR), 53 percent complete response (CR), median duration of response (DOR) of 17 months, and modest toxicity [
         <a href="#rid14">
          14
         </a>
         ]; these outcomes are at least as good as those with various antibody-based or chemotherapy treatments. (See
         <a class="local">
          'Other antibody-based therapies'
         </a>
         below and
         <a class="local">
          'Lower-intensity chemotherapy'
         </a>
         below.)
        </p>
        <p>
         Liso-cel is approved by the US Food and Drug Administration (FDA) for primary refractory DLBCL or relapse &lt;12 months after first-line systemic therapy in patients who are not eligible for HCT and for r/r DLBCL after ≥2 lines of systemic therapy.
        </p>
        <p>
         Treatment with bispecific antibody therapy and other antibody-based approaches are discussed below. (See
         <a class="local">
          'Bispecific antibody therapy'
         </a>
         below and
         <a class="local">
          'Other antibody-based therapies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1113709822">
         <span class="h2">
          Second or later relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of management with second or later relapse are to relieve symptoms, control the disease, and prolong survival, while limiting treatment-related toxicity. The likelihood of a robust and prolonged response generally decreases with successive relapses, and cure is not a realistic expectation in this setting.
        </p>
        <p>
         There is no preferred approach, and no studies have directly compared outcomes and toxicity of various treatment options. Selection of therapy is guided by availability, comorbid conditions, toxicity, and patient preference/convenience. Some patients may choose to receive palliative or supportive care because they place greater value on avoidance of toxicity than on disease response. (See
         <a class="local">
          'Palliative treatments'
         </a>
         below.)
        </p>
        <p>
         Options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bispecific antibody therapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="141793" href="/z/d/drug information/141793.html" rel="external">
          Glofitamab
         </a>
         and
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          epcoritamab
         </a>
         are CD20 x CD3 bispecific antibodies that are associated with CR in approximately 40 percent of patients. Glofitamab is administered intravenously for 12 cycles (fixed duration), while epcoritamab is given subcutaneously until disease progression. (See
         <a class="local">
          'Glofitamab'
         </a>
         below and
         <a class="local">
          'Epcoritamab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Treatment with bispecific antibodies may be associated with severe or life-threatening cytokine release syndrome (CRS) and/or rare cases of immune effector cell-associated neurotoxicity syndrome (ICANS), as described separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tafasitamab
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          lenalidomide
         </strong>
         – A humanized CD19-directed antibody that, when given with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , is associated with response in more than half of patients, but treatment requires frequent outpatient infusions and is associated with serious cytopenias in most patients. (See
         <a class="local">
          'Tafasitamab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polatuzumab
         </strong>
         <strong>
          vedotin
         </strong>
         <strong>
          /
         </strong>
         <strong>
          bendamustine
         </strong>
         <strong>
          /
         </strong>
         <strong>
          rituximab
         </strong>
         – Anti-CD79b antibody-drug conjugate that, when administered with
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , is associated with CR in up to 40 percent of patients; treatment is associated with serious cytopenias and moderate neuropathy. Bendamustine should be held or dose reduced in heavily pretreated patients, those with cytopenias, or for planned bispecific antibody therapy. (See
         <a class="local">
          'Polatuzumab/bendamustine/rituximab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Loncastuximab
         </strong>
         <strong>
          tesirine
         </strong>
         – A CD19-directed antibody-drug conjugate that is administered by infusion once per three-week cycle. It can achieve substantial responses, and treatment is associated with moderate cytopenias and edema/effusions. (See
         <a class="local">
          'Loncastuximab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selinexor
         </strong>
         – An orally available selective inhibitor of nuclear export that can achieve a response (mostly partial responses) in one-quarter of patients with r/r DLBCL, but it is associated with substantial toxicity. (See
         <a class="local">
          'Selinexor'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemotherapy
         </strong>
         – Treatment with lower-intensity chemotherapy can provide transient responses with modest adverse events. (See
         <a class="local">
          'Lower-intensity chemotherapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3204961058">
         <span class="h1">
          FRAIL PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We provide palliative and supportive care for patients whose frailty precludes other treatments. It is important to carefully discuss the goals of care, likely outcomes, and available resources for personal and medical assistance.
        </p>
        <p>
         Transfusion support, antibiotics, palliative radiation therapy, single-agent chemotherapy, or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         can be provided to relieve symptoms. (See
         <a class="local">
          'Lower-intensity chemotherapy'
         </a>
         below.)
        </p>
        <p>
         Other patients will select end-of-life care rather than the possibility of treatment-related adverse events. (See
         <a class="local">
          'Palliative treatments'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H470639468">
         <span class="h1">
          TREATMENTS
         </span>
        </p>
        <p class="headingAnchor" id="H2867477828">
         <span class="h2">
          Chimeric antigen receptor T cell therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chimeric antigen receptor (CAR)-T cell therapy is a form of immunotherapy that directs T cells against the lymphoma by ex vivo transfection of the patient's own T lymphocytes, using a gene that encodes a CAR. The manufacturing process is complex and expensive, administration is limited to qualified institutions, and the preferred product varies among institutions.
        </p>
        <p>
         CD19-directed CAR-T cell therapy has substantial activity against relapsed or refractory (r/r) DLBCL but can be associated with substantial toxicity. Age alone does not appear to be a barrier to treatment with CAR-T therapy [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comparison of CD19-directed chimeric antigen receptor
         </strong>
         <strong>
          T cell products
         </strong>
         – No prospective studies have directly compared the various CAR-T cell products. All achieved similar outcomes with r/r DLBCL, and all are associated with serious adverse events (AEs), including potentially fatal complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Commercially available CD19-directed CAR-T cell agents are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          Axicabtagene ciloleucel
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          Lisocabtagene maraleucel
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          Tisagenlecleucel
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Details of outcomes with these agents in randomized trials for r/r DLBCL are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit", section on 'Autologous hematopoietic cell transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Serious AEs associated with CAR-T cell therapy include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cytokine release syndrome
         </strong>
         – A severe systemic response to the activation and proliferation of CAR-T cells that typically manifests as high fever, flu-like symptoms, and hypotension. Some degree of cytokine release syndrome (CRS) is observed in nearly all treated patients, and it can be life threatening for some, but CRS typically responds to treatment with aggressive supportive care that includes
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         and corticosteroids, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">
          "Cytokine release syndrome (CRS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immune effector cell-associated neurotoxicity syndrome
         </strong>
         – Immune effector cell-associated neurotoxicity syndrome
         <strong>
         </strong>
         (ICANS) can be severe or life threatening, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/129618.html" rel="external">
          "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other adverse events
         </strong>
         – Other AEs include hypersensitivity reactions, serious infections, prolonged cytopenias, hypogammaglobulinemia, rare cases of hemophagocytic lymphohistiocytosis, and second malignancies, including treatment-related myeloid neoplasms (eg, myelodysplastic syndrome or acute myeloid leukemia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Facilities that dispense these agents require special certification, staff must be trained to recognize and manage AEs, and
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         (a humanized monoclonal antibody against the interleukin 6 receptor [IL-6R]) must be available for immediate administration. The US Food and Drug Administration (FDA) labels carry a boxed warning for CRS and neurologic events. CAR-T cell products are only available in the United States through a risk evaluation and mitigation strategy (REMS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred agents
         </strong>
         – The preferred CAR-T cell product varies according to the clinical setting and availability:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Second or later relapse in medically fit patients
         </strong>
         –
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          Axicabtagene ciloleucel
         </a>
         and
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         are preferred for second or later relapse in medically fit patients who did not previously receive CAR-T cell therapy, as described above. (See
         <a class="local">
          'No prior chimeric antigen receptor T cell therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          First relapse or primary refractory DLBCL in medically unfit, but not frail patients
         </strong>
         –
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          Lisocabtagene maraleucel
         </a>
         is the preferred agent for first relapse or primary refractory DLBCL in patients who are medically unfit but not frail. (See
         <a class="local">
          'First relapse or primary refractory DLBCL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Relapse after ≥2 lines of systemic therapy
         </strong>
         –
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          Axicabtagene ciloleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         , and
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         are acceptable for treatment after ≥2 lines of systemic therapy for DLBCL.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="115350" href="/z/d/drug information/115350.html" rel="external">
          Axicabtagene ciloleucel
         </a>
         ,
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         , and
         <a class="drug drug_general" data-topicid="114674" href="/z/d/drug information/114674.html" rel="external">
          tisagenlecleucel
         </a>
         are approved by the FDA for treatment of adults with r/r DLBCL after ≥2 lines of systemic therapy; in addition, axicabtagene ciloleucel is approved for treatment of adults with primary refractory DLBCL or relapse &lt;12 months after initial therapy.
        </p>
        <p class="headingAnchor" id="H3603352613">
         <span class="h2">
          Bispecific antibody therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bispecific antibodies link a CD3 antibody with another monoclonal antibody (eg, CD20) that targets the malignant B cells.
        </p>
        <p class="headingAnchor" id="H918985870">
         <span class="h3">
          Glofitamab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="141793" href="/z/d/drug information/141793.html" rel="external">
          Glofitamab
         </a>
         is a CD20 x CD3 bispecific antibody with a 2:1 tumor-to-T cell-binding configuration.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="141793" href="/z/d/drug information/141793.html" rel="external">
          Glofitamab
         </a>
         is administered intravenously for a fixed duration of 12 cycles. Treatment begins with stepped-up doses of 2.5 and 10 mg, followed by 30 mg on day 1 of cycles 2 through 12. Patients in a phase 2 study (described below) received pretreatment with
         <a class="drug drug_general" data-topicid="91388" href="/z/d/drug information/91388.html" rel="external">
          obinutuzumab
         </a>
         to mitigate CRS [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         –
         <a class="drug drug_general" data-topicid="141793" href="/z/d/drug information/141793.html" rel="external">
          Glofitamab
         </a>
         is associated with generally modest CRS, ICANS, tumor lysis syndrome, and infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – In a phase 2 study of 154 patients with r/r aggressive B cell lymphoma (71 percent with DLBCL, not otherwise specified),
         <a class="drug drug_general" data-topicid="141793" href="/z/d/drug information/141793.html" rel="external">
          glofitamab
         </a>
         was associated with 52 percent overall response rate (ORR; including 39 percent complete response [CR]) and 37 percent 12-month progression-free survival (PFS) [
         <a href="#rid16">
          16
         </a>
         ]. Most responses were observed within six weeks and were durable; three-quarters of patients with CR maintained that response at 12 months. The study enrolled patients (≥18 years) with Eastern Cooperative Oncology Group performance status 0 to 1, including one-third who had previously received CAR-T cell therapy. Response rates were similar regardless of age (&lt;65 years versus ≥65 years) and among patients who had or had not received previous CAR-T cell therapy. Grade ≥3 AEs occurred in 62 percent, including 5 percent fatal AEs and 9 percent who discontinued treatment due to AEs. Grade ≥3 AEs included CRS in 4 percent, ICANS in 3 percent, and febrile neutropenia in 3 percent.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="141793" href="/z/d/drug information/141793.html" rel="external">
          Glofitamab
         </a>
         is approved in the United States and Canada for treatment of adults with r/r DLBCL who received ≥2 lines of systemic therapy and are not eligible to receive or previously received CAR-T cell therapy [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1450741366">
         <span class="h3">
          Epcoritamab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          Epcoritamab
         </a>
         is a subcutaneously administered CD20 x CD3 bispecific antibody.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          Epcoritamab
         </a>
         is given in 28-day cycles until disease progression or unacceptable toxicity. Treatment begins with a phase of dose escalation and must be accompanied by prophylaxis for CRS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          Epcoritamab
         </a>
         is administered once weekly as stepped-up doses in weeks 1 to 3 of cycle 1 (a 0.16 mg priming dose once on day 1, followed by a 0.8 mg intermediate dose once on day 8), then as full doses once weekly through cycle 3, once every two weeks in cycles 4 to 9, and then once every four weeks in cycle 10 and thereafter [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prophylaxis for CRS is given before each dose of
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          epcoritamab
         </a>
         in cycle 1, as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prednisolone
         </strong>
         – 100 mg orally (or an intravenous equivalent) is administered 30 to 120 minutes before each
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          epcoritamab
         </a>
         dose (once daily on days 1 to 4 for the priming dose, once daily on days 8 to 11 for the intermediate dose, once daily on days 15 to 18 for the first full dose, and once daily on days 22 to 25 for the second full dose).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Diphenhydramine
         </strong>
         – 50 mg orally or intravenously (or equivalent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acetaminophen
         </strong>
         – 650 to 1000 mg orally, once daily on days 1, 8, 15, and 22 of cycle 1.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If grade ≥2 CRS occurs after the fourth
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          epcoritamab
         </a>
         dose in cycle 1, corticosteroids are given with epcoritamab for four days or until resolution of CRS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Treatment is associated with CRS, ICANS, and cytopenias.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – A multicenter study of 157 adults with r/r CD20-positive large B cell lymphoma and ≥2 prior lines of therapy (including anti-CD20 therapies) reported a 4.4-month median PFS and 63 percent ORR (including 39 percent CR); among patients with CR, the median PFS was not reached after &gt;11 months [
         <a href="#rid19">
          19
         </a>
         ]. Treatment was associated with grade ≥3 CRS in 3 percent (grade 1 or 2 CRS in 50 percent), ICANS (one patient had grade ≥3, which resulted in death; grade 1 or 2 ICANS in 50 percent), grade ≥3 neutropenia in 15 percent, and anemia in 10 percent.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="141559" href="/z/d/drug information/141559.html" rel="external">
          Epcoritamab
         </a>
         is approved by the FDA for adult patients with r/r DLBCL and high-grade B cell lymphoma after ≥2 lines of systemic therapy [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H486220651">
         <span class="h2">
          Other antibody-based therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatments using monoclonal antibodies directed against antigens expressed by DLBCL (eg, CD19, CD79b) are effective against r/r DLBCL. The choice of treatment varies with availability, toxicity, prior therapies, institutional experience, and patient preference/convenience. No prospective studies have directly compared these agents for r/r DLBCL, and no regimen has demonstrated a superior balance of efficacy and toxicity.
        </p>
        <p>
         We generally avoid use of CD19-directed monoclonal antibodies as bridging therapy prior to administration of CD19-directed CAR-T cell therapy, as discussed above. (See
         <a class="local">
          'No prior chimeric antigen receptor T cell therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H554590886">
         <span class="h3">
          Tafasitamab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          Tafasitamab
         </a>
         is a humanized anti-CD19 monoclonal antibody [
         <a href="#rid20">
          20
         </a>
         ]. Tafasitamab should be administered with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          Tafasitamab
         </a>
         is given 12 mg/kg by intravenous infusion according to the following schedule in 28-day cycles [
         <a href="#rid21">
          21
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cycle 1: Days 1, 4, 8, 15, and 22
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cycles 2 and 3: Days 1, 8, 15, and 22
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cycle 4 and beyond: Days 1 and 15
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         25 mg by mouth on days 1 to 21 of each cycle is taken in combination with
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         for a maximum of 12 cycles; tafasitamab can then be continued as monotherapy until disease progression or unacceptable toxicity. Many patients will require dose reduction of lenalidomide.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Grade ≥3 AEs occurred in half of patients, including infusion reactions (mostly in the first two cycles), neutropenia (49 percent), infections (26 percent), pneumonia (7 percent), and febrile neutropenia (6 percent) [
         <a href="#rid22">
          22
         </a>
         ]. Fatal AEs occurred in 5 percent of patients, including cerebrovascular accident, respiratory failure, progressive multifocal leukoencephalopathy, and sudden death.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – The phase 2 L-MIND study reported that among 80 patients with r/r DLBCL treated with
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         plus
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         , ORR was 60 percent (43 percent CR) with 22-month duration of response (DOR) [
         <a href="#rid22">
          22
         </a>
         ]. This study excluded patients with primary refractory disease and those with "double-hit" lymphoma. After completing 12 months of combination therapy, tafasitamab monotherapy was continued; median overall survival (OS) was 34 months, median DOR was nearly 44 months, and for patients who achieved CR, three-year OS was &gt;80 percent [
         <a href="#rid23">
          23
         </a>
         ]. During the monotherapy phase of the study, grade ≥3 AEs were neutropenia (49 percent), thrombocytopenia (17 percent), and febrile neutropenia (12 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is uncertain at present if
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          tafasitamab
         </a>
         should be avoided in patients who may later receive anti-CD19 CAR-T cell therapy.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="129156" href="/z/d/drug information/129156.html" rel="external">
          Tafasitamab
         </a>
         is approved by the FDA in combination with
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          lenalidomide
         </a>
         for the treatment of adults with r/r DLBCL who are not eligible for autologous hematopoietic cell transplantation (HCT) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4257617392">
         <span class="h3">
          Polatuzumab/bendamustine/rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">
          Polatuzumab vedotin
         </a>
         is an anti-CD79b antibody-drug conjugate that is approved for administration with
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . However, bendamustine may be avoided in patients who received prior bendamustine, those with baseline cytopenias, and those who may later receive CAR-T cell therapy or bispecific antibody therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">
          Polatuzumab vedotin
         </a>
         1.8 mg/kg over 90 minutes is given by intravenous infusion every 21 days for six cycles, in combination with
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ]. If the previous infusion was tolerated, subsequent infusions may be administered over 30 minutes. Dose reduction or discontinuation of bendamustine or growth factor support may be needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Grade ≥3 AEs occurred in two-thirds of patients (mostly cytopenias and infections) and were fatal in 7 percent [
         <a href="#rid25">
          25
         </a>
         ]. Prescribing information includes warnings for peripheral neuropathy, infusion reactions, myelosuppression, serious and opportunistic infections, progressive multifocal leukoencephalopathy (PML), tumor lysis syndrome, hepatotoxicity, and fetal toxicity [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – A trial that randomly assigned 80 transplant-ineligible patients to
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         versus bendamustine plus rituximab plus
         <a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">
          polatuzumab vedotin
         </a>
         (PBR) reported that PBR achieved superior outcomes but was associated with more grade ≥3 cytopenias and neuropathy (generally grade ≤2 and reversible) [
         <a href="#rid25">
          25
         </a>
         ]. Outcomes with PBR included superior rates of CR (40 versus 18 percent, respectively), median PFS (10 versus 4 months), and median OS (12 versus 5 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In another study,
         <a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">
          polatuzumab vedotin
         </a>
         plus
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (without
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         ) was administered as bridging therapy to 41 patients who were to receive CAR-T cell treatment [
         <a href="#rid26">
          26
         </a>
         ]. One-half of the patients successfully underwent CAR-T cell treatment, and the six-month OS was 78 percent.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="121575" href="/z/d/drug information/121575.html" rel="external">
          Polatuzumab vedotin
         </a>
         is approved by the FDA in combination with
         <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">
          bendamustine
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         for r/r DLBCL after ≥2 prior therapies [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H172771733">
         <span class="h3">
          Loncastuximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="131455" href="/z/d/drug information/131455.html" rel="external">
          Loncastuximab tesirine
         </a>
         is a CD19-directed antibody-drug conjugate.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Loncastuximab is given as an intravenous infusion over 30 minutes on day 1 of each three-week cycle:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         0.15 mg/kg for two cycles
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         0.075 mg/kg for subsequent cycles
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          Dexamethasone
         </a>
         prophylaxis should be given for three days, beginning day -1 (ie, the day before treatment).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is presently uncertain if loncastuximab should be avoided in patients who may later receive anti-CD19 CAR-T cell therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Grade ≥3 neutropenia occurred in 32 percent and thrombocytopenia in 20 percent; less common grade ≥3 AEs included edema (3 percent), pleural effusion (3 percent), and pericardial effusion (1 percent) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – A multicenter study (LOTIS-2) reported 48 percent ORR (24 percent CR) among 145 patients with refractory DLBCL or higher-risk disease (eg, double-hit, triple-hit, or transformed DLBCL) [
         <a href="#rid27">
          27
         </a>
         ]. Grade ≥3 AEs included neutropenia (26 percent), thrombocytopenia (18 percent), and liver enzyme abnormalities (17 percent); no fatal events were considered related to treatment. A phase 1 study reported 42 percent ORR and five-month DOR in patients with DLBCL [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Loncastuximab is approved by the FDA for r/r DLBCL after ≥2 prior systemic therapies [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3537596850">
         <span class="h2">
          Other treatments
         </span>
        </p>
        <p class="headingAnchor" id="H1818994479">
         <span class="h3">
          Selinexor
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          Selinexor
         </a>
         is an orally available selective inhibitor of nuclear export; the mechanism of action appears to be inhibition of nucleocytoplasmic shuttling proteins that functionally inactivate p53 and other tumor suppressor proteins [
         <a href="#rid30">
          30
         </a>
         ]. Selinexor was associated with an objective response in approximately one-quarter of highly selected patients, but it is associated with significant toxicity [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In a multicenter study, 127 heavily pretreated patients received
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          selinexor
         </a>
         60 mg by mouth on days 1 and 3 each week and achieved 28 percent ORR, including 12 percent CR; importantly, ≥60 days were required to elapse prior to enrollment in the study, which may have been selected for patients with less aggressive disease [
         <a href="#rid31">
          31
         </a>
         ]. Overall, the median DOR was 9 months, but it was 23 months in those with CR. The most common grade ≥3 AEs were thrombocytopenia (46 percent), neutropenia (24 percent), anemia (22 percent), fatigue (11 percent), hyponatremia (8 percent), and nausea (6 percent). There were no treatment-related deaths, and AEs were generally reversible and manageable with dose modifications and supportive care.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="121843" href="/z/d/drug information/121843.html" rel="external">
          Selinexor
         </a>
         is approved by the FDA for treatment of adults with r/r DLBCL after ≥2 lines of systemic therapy [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3203891162">
         <span class="h3">
          Lower-intensity chemotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lower-intensity chemotherapy can reduce the burden of disease, relieve symptoms, and prolong survival, but it is not associated with long-term disease control or cure for r/r DLBCL. The likelihood of a substantial or prolonged response diminishes with successive treatments.
        </p>
        <p>
         To lessen toxicity, we favor sequential, single-agent chemotherapy, with or without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . There is no consensus, but options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytarabine
         </strong>
         – 1500 to 2000 mg/m
         <sup>
          2
         </sup>
         intravenously every two weeks combined with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lenalidomide
         </strong>
         <strong>
         </strong>
         – This oral agent is generally combined with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid33">
          33-38
         </a>
         ]. AEs include cytopenias, infections, and increased risk for thrombosis.
         <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">
          Lenalidomide
         </a>
         may be more efficacious in r/r DLBCL with non-germinal center B cell (GCB)-like features than with GCB histology, according to a systematic review and meta-analysis [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H623054594">
         <span class="h2">
          Palliative treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who seek symptom relief with limited toxicity, palliative treatments for r/r DLBCL may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Palliative radiation therapy
         </strong>
         – To one or a few disease sites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dexamethasone
         </strong>
         – Up to 40 mg daily for two to four days can lessen symptoms for patients with end-stage DLBCL.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2854444894">
         <span class="h1">
          ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic hematopoietic cell transplantation (HCT) is used infrequently for relapsed or refractory (r/r) DLBCL due to the substantial treatment-related toxicity and availability of alternative approaches. Nevertheless, allogeneic HCT may be acceptable for selected medically fit patients who achieve a complete response (CR) or near CR after relapse following autologous HCT and chimeric antigen receptor (CAR)-T cell therapy, when antibody-based agents are not available. (See
         <a class="local">
          'Prior chimeric antigen receptor T cell therapy'
         </a>
         above.)
        </p>
        <p>
         Eligibility for allogeneic HCT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16870.html" rel="external">
          "Determining eligibility for allogeneic hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         Human leukocyte antigen (HLA)-matched related donors are preferred, but an HLA-matched unrelated donor or alternate donor sources (eg, haploidentical or umbilical cord blood) may provide acceptable grafts. (See
         <a class="medical medical_review" href="/z/d/html/3535.html" rel="external">
          "Donor selection for hematopoietic cell transplantation"
         </a>
         .)
        </p>
        <p>
         There is no consensus conditioning regimen for allogeneic HCT. Overall survival (OS) and progression-free survival (PFS) are similar after myeloablative conditioning (MAC) versus reduced intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning; MAC is generally associated with lower rates of relapse but higher rates of nonrelapse mortality [
         <a href="#rid40">
          40
         </a>
         ]. Compared with autologous HCT, allogeneic HCT is associated with considerably higher rates of transplant-related morbidity and mortality [
         <a href="#rid41">
          41
         </a>
         ]. Retrospective analysis of 101 patients who underwent allogeneic HCT for DLBCL after prior autologous HCT reported that relapse rate, PFS, and OS at three years were 30, 42, and 54 percent, respectively [
         <a href="#rid42">
          42
         </a>
         ]. Other retrospective studies reported that outcomes with NMA and RIC were comparable [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H363100825">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus for monitoring the patient with relapsed or refractory DLBCL for relapse and treatment-related toxicities. The schedule should be individualized according to concerns of the clinician and patient. For patients who achieve a complete response, we generally schedule routine clinical and laboratory evaluation every three months for the first two years and extend the interval to four or six months for the next three years.
        </p>
        <p>
         We do
         <strong>
          not
         </strong>
         perform regularly scheduled positron emission tomography or other surveillance imaging. Most relapses are suspected by history or physical examination, and only rarely is relapse identified solely on the basis of routine follow-up imaging [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1374804992">
         <span class="h1">
          CLINICAL TRIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         We strongly encourage participation in a clinical trial for patients with relapsed or refractory DLBCL.
        </p>
        <p>
         Often, there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=132087" target="_blank">
          clinicaltrials.gov
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3869548209">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120191.html" rel="external">
          "Society guideline links: Management of diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H463085484">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics – (see
         <a class="medical medical_basics" href="/z/d/html/15855.html" rel="external">
          "Patient education: Diffuse large B cell lymphoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics – (see
         <a class="medical medical_patient" href="/z/d/html/691.html" rel="external">
          "Patient education: Diffuse large B cell lymphoma in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H554200688">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Diffuse large B cell lymphoma (DLBCL) that did not respond adequately to initial therapy (primary refractory DLBCL) or that recurred after complete response (CR; relapsed DLBCL) carries an adverse prognosis. Management varies with the clinical setting and medical fitness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Repeat biopsy is generally required to confirm first relapse but may not be required for second or later relapse or primary refractory DLBCL, as discussed above. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – Includes (see
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fitness
         </strong>
         – Based on performance status  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 2
         </a>
         ) and comorbid conditions  (
         <a class="graphic graphic_table graphicRef59272" href="/z/d/graphic/59272.html" rel="external">
          table 4
         </a>
         ). Age, per se, does not determine medical fitness, but caution is urged with intensive therapy for patients ≥75 years. (See
         <a class="local">
          'Medical fitness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There are no clear distinctions among categories, and classification may vary with intercurrent disease or effects of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Medically fit
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Medically unfit but not frail
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Frail
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Restaging
         </strong>
         – Positron emission tomography/CT  (
         <a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">
          table 1
         </a>
         ), according to Lugano criteria  (
         <a class="graphic graphic_table graphicRef66651" href="/z/d/graphic/66651.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Restaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prognosis
         </strong>
         – Assessed by International Prognostic Index  (
         <a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medically fit, with second or later relapse
         </strong>
         – Management varies with prior treatments  (
         <a class="graphic graphic_algorithm graphicRef142190" href="/z/d/graphic/142190.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          No prior chimeric antigen receptor T cell therapy
         </strong>
         – For second or later relapse in patients who did not previously receive chimeric antigen receptor (CAR)-T cell therapy, we suggest CD19-directed CAR-T cell therapy rather than other treatments (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'No prior chimeric antigen receptor T cell therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prior chimeric antigen receptor T cell therapy
         </strong>
         – For a medically fit patient who relapses after receiving CAR-T cell therapy, we suggest bispecific antibody therapy rather than hematopoietic cell transplantation (HCT) or other approaches (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Prior chimeric antigen receptor T cell therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medically unfit, but not frail
         </strong>
         – Stratified as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          First relapse or primary refractory disease
         </strong>
         – For first relapse or primary refractory DLBCL in patients who are medically unfit, but not frail, we suggest
         <a class="drug drug_general" data-topicid="130728" href="/z/d/drug information/130728.html" rel="external">
          lisocabtagene maraleucel
         </a>
         (liso-cel) rather than other CAR-T cell products or other approaches (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'First relapse or primary refractory DLBCL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Second or later relapse
         </strong>
         – For second or later relapse, management varies with availability of agents, comorbid conditions, toxicity, and patient preference/convenience. Options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          CD19-directed chimeric antigen receptor T cell therapy
         </strong>
         (see
         <a class="local">
          'Chimeric antigen receptor T cell therapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Bispecific antibody
         </strong>
         <strong>
          therapy
         </strong>
         (see
         <a class="local">
          'Bispecific antibody therapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Antibody-based treatments
         </strong>
         (see
         <a class="local">
          'Other antibody-based therapies'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Other treatments
         </strong>
         (see
         <a class="local">
          'Other treatments'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Palliative treatment
         </strong>
         (see
         <a class="local">
          'Palliative treatments'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frail patients
         </strong>
         – We offer palliation and supportive care. (See
         <a class="local">
          'Frail patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatments
         </strong>
         – Include (see
         <a class="local">
          'Treatments'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chimeric antigen receptor T cell therapy
         </strong>
         – (see
         <a class="local">
          'Chimeric antigen receptor T cell therapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bispecific antibody
         </strong>
         <strong>
          therapy
         </strong>
         – CD20 x CD3 bispecific monoclonal antibodies:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Glofitamab
         </strong>
         (see
         <a class="local">
          'Glofitamab'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Epcoritamab
         </strong>
         (see
         <a class="local">
          'Epcoritamab'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibody-based treatments
         </strong>
         – Choice varies with availability, toxicity, and patient preference/convenience (see
         <a class="local">
          'Other antibody-based therapies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Tafasitamab
         </strong>
         (see
         <a class="local">
          'Tafasitamab'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Polatuzumab/
         </strong>
         <strong>
          bendamustine
         </strong>
         <strong>
          /
         </strong>
         <strong>
          rituximab
         </strong>
         (see
         <a class="local">
          'Polatuzumab/bendamustine/rituximab'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Loncastuximab
         </strong>
         (see
         <a class="local">
          'Loncastuximab'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other approaches
         </strong>
         – Include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Selinexor
         </strong>
         (see
         <a class="local">
          'Selinexor'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Lower-intensity chemotherapy
         </strong>
         (see
         <a class="local">
          'Lower-intensity chemotherapy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Palliative treatments
         </strong>
         (see
         <a class="local">
          'Palliative treatments'
         </a>
         above)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tucci A, Martelli M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 2015; 56:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu MA, DuMontier C, Murillo A, et al. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood 2019; 134:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hantel A, DuMontier C, Odejide OO, et al. Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer 2021; 127:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordoba R, Luminari S, Eyre TA. The use of frailty assessments in treating older adults with aggressive lymphomas. Br J Haematol 2021; 194:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014; 123:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salles GA, Pettengell R, Cordoba R, et al. Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leuk Lymphoma 2019; 60:1610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25:1916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour E, Chalhoub B, Suzan F, et al. Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma 2004; 45:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130:1800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westin JR, Oluwole OO, Kersten MJ, et al. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med 2023; 389:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022; 399:2294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop MR, Dickinson M, Purtill D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med 2022; 386:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson JS, Solomon SR, Arnason JE, et al. Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study [#3845]. Blood (ASH Annual Meeting Abstracts) 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020; 396:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neelapu SS, Jacobson CA, Oluwole OO, et al. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2020; 135:2106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2022; 387:2220.
          </a>
         </li>
         <li class="breakAll">
          COLUMVI. United States prescribing information. Revised June 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf (Accessed on June 29, 2023).
         </li>
         <li class="breakAll">
          EPKINLY. United States prescribing information. Revised May 2023. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf (Accessed on June 29, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol 2023; 41:2238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol 2018; 29:1266.
          </a>
         </li>
         <li class="breakAll">
          MONJUVI. United States prescribing information. Revised July 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761163s000lbl.pdf (Accessed on August 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020; 21:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021; 106:2417.
          </a>
         </li>
         <li class="breakAll">
          POLIVY. United States prescribing information. Revised June 2019. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf (Accessed on August 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 2020; 38:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv 2021; 5:2707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021; 22:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 2021; 137:2634.
          </a>
         </li>
         <li class="breakAll">
          ZYNLONTA. United States prescribing information. Revised April 2021. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761196s000lbl.pdf (Accessed on August 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 2017; 129:3175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7:e511.
          </a>
         </li>
         <li class="breakAll">
          XPOVIO. United States prescribing information. Revised June 2020. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212306s001lbl.pdf (Accessed on August 24, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26:4952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27:1902.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ivanov V, Coso D, Chetaille B, et al. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma 2014; 55:2508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zinzani PL, Pellegrini C, Derenzini E, et al. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013; 31:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czuczman MS, Trněný M, Davies A, et al. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Cancer Res 2017; 23:4127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Zhou J, Guo W, et al. Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis. Front Oncol 2021; 11:756728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120:4256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doocey RT, Toze CL, Connors JM, et al. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. Br J Haematol 2005; 131:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29:1342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezvani AR, Norasetthada L, Gooley T, et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. Br J Haematol 2008; 143:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006; 17:909.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 132087 Version 13.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25110825" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31167800" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33237587" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33713435" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The use of frailty assessments in treating older adults with aggressive lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24264230" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30702000" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488991" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lymphoma in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15359638" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28774879" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37272527" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35717989" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34904798" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study [#3845]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32888407" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32181801" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507690" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507690" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36507690" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36548927" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29444231" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29444231" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32511983" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34196165" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34196165" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31693429" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34196677" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33989558" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33211842" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33211842" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28468797" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32589977" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32589977" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18606983" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21228334" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23545991" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24506467" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23620452" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28381416" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34926259" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23007405" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16197454" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21321299" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759762" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19064981" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672295" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
